Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01612039
• Other study ID #: 3291-CL-0004
• Status: Completed
• Phase: Phase 2
• First received: June 1, 2012
• Last updated: September 26, 2016
• Start date: July 2012
• Est. completion date: April 2014

Study information

• Verified date: September 2016
• Source: Telsar Pharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health CanadaIsrael: Ministry of HealthSerbia: Medicines and Medicinal Devices of Serbia
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, randomized, double-blind, multicenter, parallel, placebo controlled study. Approximately 120 eligible patients with mild-to-moderate active ulcerative colitis will be randomized to double blind treatment of either 1,000 mg twice daily (b.i.d.) ASP3291 (2,000 mg/d) or matching placebo in a 1:1 ratio for 8 weeks.

The study hypothesis is that treatment with ASP3291 compared to placebo will improve a patient's ulcerative colitis endoscopic score from baseline to Week 8.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Documented diagnosis of ulcerative colitis by endoscopy and histology consistent with diagnosis

• Must be able to provide informed consent

• Has a Modified Baron Score of at least 2 (as determined by the investigator) at 15 cm or more from the anal verge as assessed during the screening period

• Has an Ulcerative Colitis Clinical Score (UCCS) of at least 4, with a stool frequency and rectal bleeding score of at least 1 as assessed during the screening period

• If female, is at least 2 years postmenopausal, surgically sterile per documentation provided by a medical professional, agrees to sexual abstinence, or uses two approved highly effective methods of birth control during the study period and for 30 days after the last dose of study drug

• If male, agrees to sexual abstinence or to use two highly effective methods of birth control during the study period and for 90 days after last dose; agrees to not donate sperm during the study period and for 90 days after last dose

• Willing and able to comply with the study requirements

Exclusion Criteria:

• Has a history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study

• Has severe Ulcerative Colitis as defined by an average bloody stool frequency of >6 per day and at least one of the following:

• Resting heart rate >90 bpm

• Oral temperature of >38°C (>100.4°F)

• Hemoglobin of <10.5 g/dL

• Has has undergone previous resective colonic surgery

• Has a significant or immediate risk for toxic megacolon

• Has previous diagnosis with Crohn's disease, indeterminate colitis, microscopic colitis or acute diverticulitis based on medical history

• Has an extension of disease limited to ulcerative proctitis (i.e., disease extension less than 15 cm from the anal verge)

• Has an active peptic ulcer disease based on medical history

• Shows a stool culture positive for enteric pathogens during the screening period

• Had previous treatment with tumor necrosis factor-a (TNF a) inhibitors

• Had treatment with rectal corticosteroid within 2 weeks before Day -2

• Has active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN) at screening

• Has an estimated glomerular filtration rate (using Cockroft-Gault formula corrected for body surface area) of <60 mL/min at screening

• Known history of human immunodeficiency virus antibody

• History of severe allergic or anaphylactic reactions requiring medical attention

• Has participated in another investigational study within 30 days before Visit 3

• History of drug or alcohol abuse in the past 2 years

• Has previously participated in a study with ASP3291

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• ASP3291
Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
• Placebo
Matching placebo tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Telsar Pharma Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline (Visit 2) to Week 8 (Visit 7) in Modified Baron Score		Baseline to Week 8	No
Secondary	Proportion of subjects with Modified Baron Score of 0 or 1 at Week 8 (Visit 7)		Week 8	No
Secondary	Change in Ulcerative Colitis Clinical Score of >3		Basline to Week 8	No
Secondary	Ulcerative Colitis Clinical Score stool frequency and rectal bleeding score of 0		Week 8	No